Current Report Filing (8-k)
February 13 2020 - 4:58PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 13, 2020 (February 13, 2020)
ASSERTIO THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
001-13111
(Commission File Number)
Delaware
|
|
94-3229046
|
(State or other jurisdiction of
|
|
(I.R.S. Employer Identification No.)
|
incorporation)
|
|
|
100 S. Saunders Road, Suite 300, Lake
Forest, IL 60045
(Address of principal executive offices,
with zip code)
(224) 419-7106
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
since last report)
Securities registered pursuant to Section
12(b) of the Act:
Title of each class:
|
|
Trading
Symbol(s):
|
|
Name of each exchange
on which registered:
|
Common Stock, $0.0001 par value
|
|
ASRT
|
|
The Nasdaq Stock Market LLC
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
( see General Instruction A.2. below):
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
Item 8.01 Other Events
On February 13, 2020, the Company issued a press release announcing the closing of the transaction contemplated by the Asset
Purchase Agreement dated February 6, 2020 with Collegium Pharmaceutical, Inc., as described further in Item 1.01 of our Current
Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on February 7, 2020. The Company
plans to file with the SEC a Current Report on Form 8-K disclosing the pro forma financials required under Items 2.01 and
9.01 no later than February 20, 2020. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ASSERTIO THERAPEUTICS, INC.
|
|
|
|
|
|
Date: February 13, 2020
|
By:
|
/s/ Daniel A. Peisert
|
|
|
Daniel A. Peisert
|
|
|
Senior Vice President and Chief Financial Officer
|
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assertio (NASDAQ:ASRT)
Historical Stock Chart
From Apr 2023 to Apr 2024